Summary

Results from the Efficacy and Safety Study of OncoVEX Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to GM-CSF in Melanoma [OPTiM; NCT00769704; Andtbacka RHI et al. J Clin Oncol 2013 (suppl; abstr LBA9008)] showed that a genetically modified version of herpes simplex virus type 1 (talimogene laherparepvec), is safe and improves durable response rate in patients with unresectable stage IIIB-IV melanoma.